135
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Ivermectin Treatment Coverage Validation in Two Onchocerciasis Endemic Districts in Ethiopia: A Community-Based Cross-Sectional Study, 2019

ORCID Icon, ORCID Icon, , , , , ORCID Icon, , , , & ORCID Icon show all
Pages 137-144 | Published online: 18 Jan 2021

References

  • Tekle AH, Zouré HG, Noma M, et al. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results. Infect Dis Poverty. 2016;5(1):66. doi:10.1186/s40249-016-0160-7
  • World Health Organization. Onchocerciasis key fact sheet; 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/onchocerciasis. Accessed December 18, 2020.
  • Little MP, Breitling LP, Basáñez MG, Alley ES, Boatin BA. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet. 2004;363(9420):1514–1521. doi:10.1016/S0140-6736(04)16151-5
  • Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatology. 1993;129(3):260–269. doi:10.1111/j.1365-2133.1993.tb11844.x
  • Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145–2191. doi:10.1016/S0140-6736(15)61340-X
  • WHO. Regional Strategic Plan for NTDs in the African Region; 2020.
  • WHO/APOC. Status of Onchocerciasis in APOC Countries; 2013.
  • Crump A, Morel CM, Omura S. The onchocerciasis chronicle: from the beginning to the end? Trends Parasitol. 2012;28(7):280–288. doi:10.1016/j.pt.2012.04.005
  • World Health Organization. Report of the External Mid-Term Evaluation of the African Programme for Onchocerciasis Control. African Programme for Onchocerciasis Control; 2010.
  • World Health Organization. Guidelines for Stopping Mass Drug Administration and Verifying Elimination of Human Onchocerciasis: Criteria and Procedures. World Health Organization; 2016.
  • Dana D, Debalke S, Mekonnen Z, et al. A community-based cross-sectional study of the epidemiology of onchocerciasis in unmapped villages for community directed treatment with ivermectin in Jimma Zone, southwestern Ethiopia. BMC Public Health. 2015;15(1):595. doi:10.1186/s12889-015-1888-x
  • Dori GU, Belay T, Belete H, Panicker KN, Hailu A. Parasitological and clinico-epidemiological features of onchocerciasis in West Wellega, Ethiopia. J Parasitic Dis. 2012;36(1):10–18. doi:10.1007/s12639-011-0063-2
  • HR PM T, Muñoz B, Greene BM, Greene B. Impact of MDA of onchocerciasis with ivermectin on the transmission of infection. Science. 1990;250(4977):116–118. doi:10.1126/science.2218502
  • UN. Transforming our world, the 2030 agenda for sustainable development; 2020. Available from: sustainabledevelopment.un.org. Accessed December 18, 2020.
  • Meribo K, Kebede B, Feleke SM, et al. Review of Ethiopian onchocerciasis elimination programme. Ethiop Med J. 2017;55(Suppl 1):55.
  • WHO. Neglected Tropical Diseases-Onchocericiasis Data; 2019.
  • Griswold E, Eigege A, Ityonzughul C, et al. Evaluation of treatment coverage and enhanced mass drug administration for onchocerciasis and lymphatic filariasis in five local government areas treating twice per year in Edo state, Nigeria. Am J Trop Med Hyg. 2018;99(2):396–403. doi:10.4269/ajtmh.17-1004